Announcements Trials
Browse Landscape

Status

Recruiting 6Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 206Neoplasms 191Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 89Prostatic Neoplasms 78Lung Neoplasms 73Multiple Myeloma 49Head and Neck Neoplasms 47Melanoma 46Pancreatic Neoplasms 43Neoplasm Metastasis 42Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 40Recurrence 34Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Ovarian Neoplasms 31Glioblastoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Glioma 27Uterine Cervical Neoplasms 26Sarcoma 26Lymphoma, Non-Hodgkin 26Lymphoma 26Stomach Neoplasms 25Lymphoma, Follicular 24Carcinoma, Renal Cell 24Esophageal Neoplasms 22Colonic Neoplasms 22Rectal Neoplasms 21

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hemorrhage × 90 days × Clear all
NCT07527832 2026-06-03

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Pfizer

Completed
1,000 enrolled
Gastrointestinal

Hemorrhage, Colorectal Neoplasms

NCT06170619 2026-06-01

OCCLUDE

Boston Scientific Corporation

Completed
125 enrolled

Hemorrhage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡